Cargando…
The STAT3 inhibitor galiellalactone inhibits the generation of MDSC‐like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors
BACKGROUND: The transcription factor signal transducer and activator of transcription 3 (STAT3) is implicated in cancer drug resistance, metastasis, and immunosuppression and has been identified as a promising therapeutic target for new anticancer drugs. Myeloid‐derived suppressor cells (MDSCs) play...
Autores principales: | Hellsten, Rebecka, Lilljebjörn, Lisa, Johansson, Martin, Leandersson, Karin, Bjartell, Anders |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771992/ https://www.ncbi.nlm.nih.gov/pubmed/31348843 http://dx.doi.org/10.1002/pros.23885 |
Ejemplares similares
-
Galiellalactone Inhibits Stem Cell-Like ALDH-Positive Prostate Cancer Cells
por: Hellsten, Rebecka, et al.
Publicado: (2011) -
STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population
por: Canesin, Giacomo, et al.
Publicado: (2020) -
Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer
por: Witt, Kristina, et al.
Publicado: (2021) -
The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells
por: Hellsten, Rebecka, et al.
Publicado: (2022) -
Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer
por: Thaper, Daksh, et al.
Publicado: (2018)